Sofpironium bromide - Brickell Biotech

Drug Profile

Sofpironium bromide - Brickell Biotech

Alternative Names: BBI-4000

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bodor Laboratory
  • Developer Brickell Biotech; Kaken Pharmaceutical
  • Class Pyrrolidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperhidrosis

Most Recent Events

  • 20 Feb 2018 Additional positive efficacy and adverse events data from a phase IIb trial in Hyperhidrosis released by Brickell Biotech
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hyperhidrosis in Dominican Republic (Topical, Gel)
  • 24 Oct 2017 Brickell Biotech plans a pivotal phase III trial for Hyperhidrosis in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top